Zobrazeno 1 - 10
of 649
pro vyhledávání: '"Ichiro, Yoshino"'
Autor:
Kaoru Kaseda, Keisuke Asakura, Yasushi Shintani, Jiro Okami, Shinichi Toyooka, Yukio Sato, Shun-Ichi Watanabe, Masayuki Chida, Hidemi Suzuki, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date, The Japanese Joint Committee of Lung Cancer Registry
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Sarcomatoid carcinoma of the lung is a rare histological type of non-small cell lung cancer with a poor prognosis. We aimed to investigate the clinicopathological characteristics and prognostic factors of surgically resected sarco
Externí odkaz:
https://doaj.org/article/746bc39095554c20b9232bc0a831adec
Autor:
Shigehiro Yagishita, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Hidetoshi Hayashi, MD, PhD, Satoru Miura, MD, PhD, Koji Tamada, MD, PhD, Hiroshi Kagamu, MD, PhD, Akinobu Hamada, PhD, Mayu Ohuchi, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Satoshi Hara, MD, Takashi Kijima, MD, PhD, Fujita Masaki, MD, PhD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Masahiro Tatsuno, MSc, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100683- (2024)
Introduction: This study validated real-world pharmacokinetic (PK) data using an established population PK (PopPK) model for atezolizumab in Japanese patients with NSCLC and explored the relationship between PK parameters, effectiveness, and adverse
Externí odkaz:
https://doaj.org/article/5313a5b432ab4c3892187d0d69ddf659
Autor:
Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada, Ichiro Yoshino, Jiro Okami, Kazuhisa Takahashi, Norihiko Ikeda, Masayuki Tanahashi, Yuichi Tambo, Haruhiro Saito, Shinichi Toyooka, Hidetoshi Inokawa, Toyofumi Chen‐Yoshikawa, Toshihide Yokoyama, Tatsuro Okamoto, Noriko Yanagitani, Masahide Oki, Makoto Takahama, Kenji Sawa, Hirohito Tada, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Kazuto Nishio
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 305-316 (2024)
The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC). Although the primary endpo
Externí odkaz:
https://doaj.org/article/5ef9670861fa45fda1c2e13f031a8170
Autor:
Teruaki Mizobuchi, Akihiro Nomoto, Hironobu Wada, Naoyoshi Yamamoto, Mio Nakajima, Takehiko Fujisawa, Hidemi Suzuki, Ichiro Yoshino
Publikováno v:
Radiation Oncology, Vol 18, Iss 1, Pp 1-8 (2023)
Abstract Purpose This study aimed to compare the outcomes of patients with ground-grass opacity (GGO)-dominant non-small cell lung cancer (NSCLC) who were treated with carbon ion radiotherapy (CIRT) versus segmentectomy. Methods A retrospective revie
Externí odkaz:
https://doaj.org/article/729fc7024fad4b3caf9708bb2ea40c61
Publikováno v:
Thoracic Cancer, Vol 14, Iss 22, Pp 2229-2232 (2023)
Abstract Bronchopleural fistulas are rare complications of bevacizumab treatment. Herein, we report a case of bronchopleural fistula after bevacizumab therapy. The patient was a 65‐year‐old man with lung cancer who underwent a right lower lobecto
Externí odkaz:
https://doaj.org/article/311f07a9736b4b969e905f864ccb3064
Autor:
Takehito Shukuya, Kazuhisa Takahashi, Yasushi Shintani, Keita Miura, Ikuo Sekine, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Tomoya Kawaguchi, Nobuyuki Yamamoto, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 14, Iss 3, Pp 1274-1285 (2023)
Abstract Background Cancer cachexia is a syndrome that does not fully recover with nutritional support and causes appetite loss and body weight loss. It worsens a patient's quality of life and prognosis. In this study, the epidemiology of cachexia in
Externí odkaz:
https://doaj.org/article/68660320fdbd4d5392bc951bfce4c97d
Autor:
Taisuke Kaiho, Hidemi Suzuki, Atsushi Hata, Hiroki Matsumoto, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Immune checkpoint molecules such as programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have revolutionized the field of lung cancer treatment. As part of our study, we examined the role of these proteins in acute rejection in a mouse mod
Externí odkaz:
https://doaj.org/article/eced30ae2d39482abc151933646f56c1
Autor:
Yuya Nobori, MD, Masaki Anraku, MD, Yoshikane Yamauchi, MD, Mingyon Mun, MD, Ichiro Yoshino, MD, Jun Nakajima, MD, PhD, Norihiko Ikeda, MD, Haruhisa Matsuguma, MD, Takekazu Iwata, MD, Yasushi Shintani, MD, Mitsuo Nakayama, MD, Takahiko Oyama, MD, Masayuki Chida, MD, Hiroaki Kuroda, MD, Hiroshi Hashimoto, MD, Yoko Azuma, MD, Kazuhito Funai, MD, Makoto Endoh, MD, Yukari Uemura, PhD, Masafumi Kawamura, MD
Publikováno v:
JTCVS Open, Vol 13, Iss , Pp 411-422 (2023)
Objective: There is little evidence of the outcome of pulmonary metastasectomy for uterine tumors when comparing different histologies. This study aimed to delineate the primary histology that leads to more favorable outcomes after pulmonary metastas
Externí odkaz:
https://doaj.org/article/720bde3fe8d6475a9e89d880fc1aeeeb
Autor:
Hiroyuki Ito, Hiroshi Date, Yasushi Shintani, Etsuo Miyaoka, Ryoichi Nakanishi, Mitsutaka Kadokura, Shunsuke Endo, Masayuki Chida, Ichiro Yoshino, Hidemi Suzuki, the Japanese Joint Committee of Lung Cancer Registry
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Objective We studied the prognosis and clinicopathological background of lung adenocarcinoma predominance among patients who underwent lobectomy using data from the Japanese Joint Committee of Lung Cancer Registry. Methods Two thousand eight
Externí odkaz:
https://doaj.org/article/c1036b2d73d6441fa209c971c9c8cb6b
Autor:
Hiroki Matsumoto, Hidemi Suzuki, Takahiro Yamanaka, Taisuke Kaiho, Atsushi Hata, Terunaga Inage, Takamasa Ito, Toshiko Kamata, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Publikováno v:
Life, Vol 13, Iss 10, p 2042 (2023)
Antibody-mediated rejection (AMR) is a risk factor for chronic lung allograft dysfunction, which impedes long-term survival after lung transplantation. There are no reports evaluating the efficacy of the single use of anti-CD20 antibodies (aCD20s) in
Externí odkaz:
https://doaj.org/article/aa5479d170a44e369c4a00e9097f255c